Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia [0.03%]
体外循环和一过性肾缺血后急性肾脏损伤中的游离血红素及血红素结合蛋白水平变化
Robert Greite,Sebastian Schott,Li Wang et al.
Robert Greite et al.
Free heme is released from hemoproteins during hemolysis or ischemia reperfusion injury and can be pro-inflammatory. Most studies on nephrotoxicity of hemolysis-derived proteins focus on free hemoglobin (fHb) with heme as a prosthetic group...
Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data [0.03%]
基于欧洲临床试验登记处数据评估早期临床试验中影响受试者招募率的相关因素
Paloma Moraga Alapont,Paula Prieto,Mikel Urroz et al.
Paloma Moraga Alapont et al.
Effective participant recruitment is a critical challenge in clinical trials. Inadequate enrollment of participants can precipitate delays, escalated costs, and compromise scientific integrity. Despite its relevance, particularly during the...
Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey [0.03%]
DPYD和UGT1A1药物基因组筛查的患者及卫生专业人员接受度横断面调查研究
Sarah Glewis,Mei Krishnasamy,Senthil Lingaratnam et al.
Sarah Glewis et al.
This study explored the acceptability of a novel pharmacist-led pharmacogenetics (PGx) screening program among patients with cancer and healthcare professionals (HCPs) taking part in a multicenter clinical trial of PGx testing (PACIFIC-PGx ...
Multicenter Study
Clinical and translational science. 2023 Dec;16(12):2700-2708. DOI:10.1111/cts.13664 2023
Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies [0.03%]
托福西玛在中国高胆固醇血症患者中的药代动力学和LDL-C暴露-效应关系分析：I、II 和III 期研究结果
Shuling Yan,Xia Zhao,Qiushi Xie et al.
Shuling Yan et al.
Tafolecimab, a novel fully human monoclonal antibody targeting PCSK9, has been assessed in Chinese healthy volunteers and patients with hypercholesterolemia. This analysis is to develop and qualify a population pharmacokinetics (PopPKs)/LDL...
Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease [0.03%]
儿童 leukocyte细胞源趋化因子2与非酒精性肝病相关性研究
Diego Paine-Cabrera,Lisa K Harvey,Dakota R Robarts et al.
Diego Paine-Cabrera et al.
Non-alcoholic fatty liver disease (NAFLD), newly renamed metabolic dysfunction-associated liver disease (MASLD), is a leading cause of liver disease in children and adults. There is a paucity of data surrounding potential biomarkers and the...
AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study [0.03%]
一项评价AZD9567与泼尼松龙治疗活动性类风湿关节炎患者有效性和安全性的IIa期、随机(1:1)、双盲研究
Jacob M van Laar,Alejhandra Lei,Mary Safy-Khan et al.
Jacob M van Laar et al.
Oral corticosteroid use is limited by side effects, some caused by off-target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 is a selective, nonsteroidal glucocorticoid receptor modulator. The efficacy, ...
Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial [0.03%]
恩巴普拉坦治疗COVID-19肺炎的疗效和安全性II期随机临床试验结果
John E McKinnon,Joel Santiaguel,Claudia Murta de Oliveira et al.
John E McKinnon et al.
Enpatoran is a selective inhibitor of toll-like receptors 7 and 8 (TLR7/8) that potentially targets pro-inflammatory pathways induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A phase II study conducted in Brazil, the...
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID-19 patients with pre-existing comorbidities [0.03%]
潜在的生物标志物在合并症住院COVID-19患者的死亡结果预测中的作用
Ruth Lizzeth Madera-Sandoval,Arturo Cérbulo-Vázquez,Lourdes Andrea Arriaga-Pizano et al.
Ruth Lizzeth Madera-Sandoval et al.
The difficulty in predicting fatal outcomes in patients with coronavirus disease 2019 (COVID-19) impacts the general morbidity and mortality due to severe acute respiratory syndrome-coronavirus 2 infection, as it wears out the hospital serv...
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX [0.03%]
种族敏感性评估：在POLARIX研究中评估新药Polatuzumab vedotin在接受首次治疗的非霍奇金弥漫大B细胞淋巴瘤患者中的药代动力学（亚洲和非亚洲人种）
Michael Z Liao,Rong Deng,Leonid Gibiansky et al.
Michael Z Liao et al.
This ethnic sensitivity analysis used data from the phase III POLARIX study (NCT03274492) to assess polatuzumab vedotin pharmacokinetics (PKs) in Asian versus non-Asian patients with previously untreated diffuse large B-cell lymphoma and ex...
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study [0.03%]
第三代头孢菌素耐药病原体引起的急性肾盂肾炎的治疗：一项拉氧氟作为口服药物在静脉碳青霉烯之后转换治疗的随机对照研究——一项初步研究
Apichot So-Ngern,Supunnee Jirajariyavej,Huttaya Thuncharoon et al.
Apichot So-Ngern et al.
The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third-generation cephalosporin resistant Enterobacteriaceae (3-GCrEC) needs to be invest...
Randomized Controlled Trial
Clinical and translational science. 2023 Dec;16(12):2709-2718. DOI:10.1111/cts.13665 2023